Free Trial

89bio Q3 2023 Earnings Report

89bio logo
$8.08 -0.88 (-9.82%)
As of 03/28/2025 04:00 PM Eastern

89bio EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
$1.00 million
Expected Revenue
$0.38 million
Beat/Miss
Beat by +$620.00 thousand
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release
Remove Ads

89bio Earnings Headlines

ETNB Crosses Above Key Moving Average Level
DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
Analysts Set 89bio, Inc. (NASDAQ:ETNB) Price Target at $27.56
89bio initiated with a Neutral at Goldman Sachs
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat